C12N1/16

STRAIN FOR PRODUCING LONG-CHAIN DICARBOXYLIC ACIDS AND FERMENTATION METHOD THEREFOR

Provided are a Candida tropicalis strain Am2525, with the preservation number thereof being CCTCC NO: M 2019419, and a method for producing long-chain dicarboxylic acids by means of fermenting the strain. The method for producing the long-chain dicarboxylic acids comprises preparing a seed solution by means of the Candida tropicalis strain Am2525 and producing the long-chain dicarboxylic acids via fermentation of the seed solution. Compared with the parent, the Candida tropicalis strain Am2525 has an enhanced resistance to the toxicity of a substrate decane, improves the productivity of long-chain dicarboxylic acids, reduces the cost of production, subsequent separation and purification are simple, and the fermentation production process is easy to implement on a large scale.

LONG-TERM CELL-CULTIVATION USING POLYIMIDE POROUS MEMBRANE AND CELL-CRYOPRESERVATION METHOD USING POLYIMIDE POROUS MEMBRANE
20170369838 · 2017-12-28 ·

The invention relates to a long term cell culturing method and a cell culturing apparatus and kit that employ a porous polyimide film. The invention further relates to a cell cryopreservation method and kit employing the porous polyimide film.

FERMENTATION PATHWAY FOR PRODUCING MALONIC ACID

The present disclosure provides an engineered microorganism capable of producing malonic acid, malonate, esters of malonic acid, or mixtures thereof. The engineered microorganism includes a malonate-semialdehyde dehydrogenase that is heterologous to a native form of the engineered microorganism and comprises at least 90% sequence identity to any one of SEQ ID Nos: 7, 9, 11, 13, 15, 17, 19, 21, 23, 27, 29, and 31, wherein the engineered microorganism is capable of producing about 9 g/L to about 250 g/L of malonic acid, malonate, esters of malonic acid, or mixtures thereof.

FERMENTATION PATHWAY FOR PRODUCING MALONIC ACID

The present disclosure provides an engineered microorganism capable of producing malonic acid, malonate, esters of malonic acid, or mixtures thereof. The engineered microorganism includes a malonate-semialdehyde dehydrogenase that is heterologous to a native form of the engineered microorganism and comprises at least 90% sequence identity to any one of SEQ ID Nos: 7, 9, 11, 13, 15, 17, 19, 21, 23, 27, 29, and 31, wherein the engineered microorganism is capable of producing about 9 g/L to about 250 g/L of malonic acid, malonate, esters of malonic acid, or mixtures thereof.

Method for production of moth pheromones in yeast

The present disclosure relates to methods for production of (Z)-11-hexadecen-1-ol in a yeast cell using desaturases and fatty acyl-CoA reductase. Also disclosed are methods for production of (Z)-11-hexadecenal in a yeast cell. Also disclosed are methods for production of (Z)-11-hexadecen-1-yl acetate in a yeast cell. The disclosure also provides for nucleic acid constructs and yeast cells useful for performing the present methods, as well as to pheromone compositions.

Method for production of moth pheromones in yeast

The present disclosure relates to methods for production of (Z)-11-hexadecen-1-ol in a yeast cell using desaturases and fatty acyl-CoA reductase. Also disclosed are methods for production of (Z)-11-hexadecenal in a yeast cell. Also disclosed are methods for production of (Z)-11-hexadecen-1-yl acetate in a yeast cell. The disclosure also provides for nucleic acid constructs and yeast cells useful for performing the present methods, as well as to pheromone compositions.

Replication-defective adenoviruses comprising nucleic acids encoding SARS-CoV-2 s glycoprotein and modified N protein comprising an endosomal targeting sequence
11684668 · 2023-06-27 · ·

Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.

Replication-defective adenoviruses comprising nucleic acids encoding SARS-CoV-2 s glycoprotein and modified N protein comprising an endosomal targeting sequence
11684668 · 2023-06-27 · ·

Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.

CONTROLLED GROWTH OF MICROORGANISMS
20230193191 · 2023-06-22 ·

It can be useful to regulate the growth of microbial cells. Some embodiments herein provide genetically engineered microbial cells that can produce bacteriocins to control the growth of microbial cells. In some embodiments, microbial cells are contained within a desired environment. In some embodiments, contaminating microbial cells are neutralized. In some embodiments, a first microbial cell type regulates the growth of a second microbial cell type so as to maintain a desired ratio of the two cell types.

CONTROLLED GROWTH OF MICROORGANISMS
20230193191 · 2023-06-22 ·

It can be useful to regulate the growth of microbial cells. Some embodiments herein provide genetically engineered microbial cells that can produce bacteriocins to control the growth of microbial cells. In some embodiments, microbial cells are contained within a desired environment. In some embodiments, contaminating microbial cells are neutralized. In some embodiments, a first microbial cell type regulates the growth of a second microbial cell type so as to maintain a desired ratio of the two cell types.